Rituximab treatment in ANCA-associated vasculitis patients: outcomes of a real-life experience from an observational cohort.

ABSTRACT: Rituximab is a first-line therapy in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Among previous studies evaluating its efficacy, the Hispanic/Latino population has been underrepresented. This study aimed to assess the outcomes of AAV patients treated with rituximab in a tertiary care center in Mexico. This is a retrospective cohort study including patients with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), or renal-limited vasculitis (RLV), who received at least one dose of rituximab (induction or maintenance therapy) from January 2014 to October 2020. Demographic, clinical, serological, histopathological, and treatment-related variables were retrieved. Outcomes were the rate of remission at 6 months during induction and

SUBMITTER: Carranza-Enriquez F 

PROVIDER: S-EPMC9065666 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature